Needham & Company Maintains a 'Hold' on Forest Laboratories (FRX); Christmas Comes Early
Tweet Send to a FriendGet Alerts FRX Hot Sheet
Price: $38.53 -0.44%
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
9 Buy, 9 Hold, 3 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade FRX Now!
Needham & Company maintains a 'Hold' on Forest Laboratories (NYSE: FRX).
Analyst, Elliot Wilbur, said, "...Given its novel mechanism of action and positive impact on abdominal pain, we continue to believe that Linzess is a potential “gamechanger” for treating IBS-C and CC and the most promising of FRX’s “late eight” product stable of Lexapro revenue replacements. That being said, while we believe FRX shares already embedded the highly expected linaclotide approval, commercialization expectation hurdle appears high with consensus sales approaching $800MM in FY2016. We currently model sales of $594MM in FY2017."
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $35.04 yesterday, with a 52 week range of $28.47-$36.44.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Elliot Wilbur, said, "...Given its novel mechanism of action and positive impact on abdominal pain, we continue to believe that Linzess is a potential “gamechanger” for treating IBS-C and CC and the most promising of FRX’s “late eight” product stable of Lexapro revenue replacements. That being said, while we believe FRX shares already embedded the highly expected linaclotide approval, commercialization expectation hurdle appears high with consensus sales approaching $800MM in FY2016. We currently model sales of $594MM in FY2017."
For an analyst ratings summary and ratings history on Forest Laboratories click here. For more ratings news on Forest Laboratories click here.
Shares of Forest Laboratories closed at $35.04 yesterday, with a 52 week range of $28.47-$36.44.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- UPDATE: Vanda Pharmaceuticals (VNDA) Opens Higher; Lazard Raises PT to $17
- Goldman Sachs Upgrades Ruckus Wireless (RKUS) to Buy, 'Pullback Creates Opportunity'
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Needham & Company
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
